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Summary
Forkhead transcription factor Foxa2 activates genes involved in hepatic lipid metabolism and is regulated by insulin. Acti-
vation of Foxa2 in the liver leads to increased oxidation and secretion of fatty acids in the form of triacylglycerols (TAGs),
a process impaired in type 2 diabetes. Here, we demonstrate that Foxa2 is coactivated by PPARg coactivator b (Pgc-1b).
Adenoviral expression of Foxa2 and Pgc-1b in livers of ob/obmice results in decreased hepatic TAG content and increased
plasma TAG concentrations. In addition, the concerted action of Foxa2/Pgc-1b activates genes in mitochondrial b oxidation
and enhances fatty acid metabolism. Furthermore, Foxa2/Pgc-1b induce the expression of microsomal transfer protein,
thereby increasing apoB-containing VLDL secretion. This process is inhibited by insulin through a Foxa2-dependent mech-
anism. These data demonstrate that Foxa2/Pgc-1b regulate hepatic lipid homeostasis by affecting the clearance rate of fatty
acids through oxidation and/or secretion of lipids in response to insulin.Introduction
Triacylglycerols (TAGs) are the most concentrated biological
fuels available, making them an ideal form of energy storage.
However, because of their extreme hydrophobicity, regulated
transport into the polar medium of circulating blood is only pos-
sible in the form of TAG-rich lipoproteins. Two types of these
particles are known, namely chylomicrons that are secreted by
enterocytes of the gut in response to dietary TAG, and very-
low-density lipoprotein (VLDL) secreted by hepatocytes of the
liver in response to de novo synthesized TAGs (Shelness and
Sellers, 2001). Most of the TAGs transported in the plasma dur-
ing the postabsorptive phase are associated with chylomicrons.
Hypertriglyceridemia, which is characterized by an increase of
plasma TAG concentration, has been shown to be a component
of the metabolic syndrome and is an independent risk factor for
coronary artery disease (Rubins, 2000; Ginsberg, 2002). Fur-
thermore, increasing evidence suggests that postprandial hy-
perlipidemia also contributes to the development of atheroscle-
rosis (Heine and Dekker, 2002).
The assembly and secretion of VLDL is a complex process
that brings together the very large and highly amphipathic
apoB polypeptide and different classes of lipids in a fixed se-
quence. In humans, the liver produces VLDL particles that are
composed of full-length apoB-100, while the small intestine pro-
duces chylomicrons containing apoB-48 (amino terminal 48%
of apoB-100; Shelness and Sellers, 2001; Gibbons et al.,
2004). The secretion and assembly of VLDL-associated triglyc-
erides is regulated at various levels. The key enzyme controlling
VLDL synthesis is themicrosomal triacylglycerol transfer protein
(MTP). Genetic ablation of MTP prevents the secretion of VLDL
into the plasma compartment by inhibiting the generation of
apoB-containing VLDL precursors (Raabe et al., 1998). Further-
more, overexpression of MTP results in increased secretion of
VLDL triglycerides and apoB (Horton, 2002). In addition to regu-
lation by MTP, VLDL synthesis and secretion is regulated byCELL METABOLISM 3, 99–110, FEBRUARY 2006 ª2006 ELSEVIER INCsubstrate availability, which in turn is regulated by key lipogenic
enzymes, i.e., fatty acid synthase (FAS), and acetyl-CoA carbox-
ylase (ACC). Activities of these enzymes in turn are controlled by
the sterol regulatory element binding protein-1c (SREBP-1c;
Horton, 2002).
Insulin has been shown to inhibit VLDL output from the liver of
rats and humans, and exogenous insulin administration also
suppresses the secretion of VLDL triacylglycerol and apoB in
humans (Durrington, et al., 1982; Patsch et al., 1983; Patsch
et al., 1986). This inhibition of VLDL assembly/secretion con-
trasts the regulation of VLDL synthesis by SREBP-1c, as insulin
is a known activator of SREBP-1c. Although the mechanism is
not completely understood, it is believed that insulin interferes
with thematuration phase of VLDL assembly but does not inhibit
the overall lipolytic mobilization of hepatic cytosolic TAG. In-
stead, insulin signaling mediates the return of TAGs to the cyto-
solic pool, an effect similar to that ofMTP inhibition, which is also
required for the efficient production of the TAG-rich VLDL pre-
cursors but has no effect on TAG synthesis.
On a cellular level, the metabolic responses to changes in
plasma insulin levels are mediated by the insulin/PI3-kinase/
Akt signaling pathway, which regulates the activity of several
forkhead transcription factors. We have recently shown that
the forkhead transcription factor A2 (Foxa2) is phosphorylated
in response to insulin signaling, resulting in inhibition of its tran-
scriptional activity by nuclear exclusion (Wolfrum et al., 2003;
Wolfrum et al., 2004). The forkhead box A family of transcription
factor in mammals include three genes designated as Foxa1,
Foxa2, and Foxa3 (Kaestner et al., 1994). All three members
share a high homology and a conserved winged-helix DNA tar-
get site (Brennan, 1993); however, their biological functions are
diverse. Foxa2 plays a central role in maintaining lipid and glu-
cose homeostasis by regulating gene expression of rate-limiting
enzymes in response to insulin inactivation (Wolfrum et al.,
2004). Induction of Foxa2 activity at low-insulin concentrations
leads to an increase in mitochondrial and peroxisomal. DOI 10.1016/j.cmet.2006.01.001 99
A R T I C L Eb oxidation, ketone body production, and plasma TAG concen-
tration. These observed changes in hepatic lipid metabolism are
mirrored by the effect of the coactivating factor peroxisome pro-
liferator g coactivator b (PGC-1b) on hepatic lipid metabolism
(Lin et al., 2005).
PGC-1b is a recently identified transcriptional coactivator with
high sequence similarity to PGC-1a. Both factors show similar
tissue distribution; however, their capacity to regulate gene ex-
pression varies (Lin et al., 2002). While PGC-1a activates genes
encoding enzymes of gluconeogenesis and mitochondrial bio-
genesis/fatty acid oxidation, PGC-1b solely activates the latter
pathways (Lin et al., 2002). Thus, it was recently shown that
overexpression of PGC-1b leads to an increase in mitochondrial
b oxidation as well as to an increase in plasma TAG concentra-
tion (Lin et al., 2005). In this study, we demonstrate that Pgc-1b
is a coactivator of Foxa2 and that the concerted action of these
factors regulate fatty acid b oxidation and TAG-associated VLDL
secretion from the liver.
Results
Coactivation of Foxa2 by Pgc-1b through Foxa2 domain
aa 266–340
In spite of Foxa1 and 2’s nearly identical DNA winged-helix
domain and their ability to bind to the same Foxa binding sites
in vitro, Foxa1 and Foxa2 have been shown to transactivate dif-
ferent target genes and regulate diverse biological pathways. In
an attempt to identify the sequences that are responsible for
conferring transcriptional activity and specificity, we generated
hybrids of both factors (Figure 1A) and analyzed their ability to
activate transcription by reporter gene assays. The Foxa hybrid
constructs were cotransfected into HepG2 cells along with re-
porter constructs containing 50 regulatory sequences of CptI
andMcad. Both promoters harbor conserved Foxa binding sites
and are activated by Foxa2 (Wolfrum et al., 2004). To ensure
equal transfection efficiencies of the hybrid vectors, all con-
structs were HA tagged, and the relative expression of Foxa1,
2, and hybrid proteins were assayed by Western blotting (data
not shown). Figures 1B and 1C show that, when expressed at
similar levels, Foxa2 is a stronger transcriptional activator than
Foxa1, an observation that we reported previously (Duncan
et al., 1998). The differences in the ability of the Foxa-hybrids
to activate both CptI and Mcad promoters allowed us to identify
a 74 amino acid residue region (266–340), hereafter referred to
as domain A, that is responsible for the higher transactivation
potential of Foxa2 (Figures 1A–1C). The exchange of this domain
in Foxa1 with the corresponding coding sequence from Foxa2
(Hyb.) restored the transcriptional activity of Foxa1 to levels ob-
served for Foxa2 (Figures 1B and 1C).
We speculated that the observed differences in transactiva-
tion capacity might be due to the recruitment of transcriptional
coactivators. Candidate factors that may interact with Foxa2 in-
cluded members of the PGC family because (1) they have previ-
ously been shown to regulate genes that are known targets of
Foxa2, and (2) Pgc-1a interaction has been reported with
Foxo1, a different member of the forkhead box transcription fac-
tor family. Interaction of Pgc-1a and b isoformswith either Foxa1
or Foxa2 were first assessed in amammalian two-hybrid system
in which Pgc-1a or Pgc-1b (baits) were fused with the Gal4 DNA
binding domain, and Foxa1, 2, or domain A (target proteins) were
expressed as a fusion protein with the VP16 transactivation100Figure 1. Generation of Foxa1/Foxa2 hybrids
A) Schematic representation of the Foxa1/Foxa2 hybrids. Sequence from Foxa2 is
denoted in red, while sequence from Foxa1 is shown in yellow.
B)HepG2 cells were transfected with Foxa1, Foxa2, or Hybrid expression vectors,
pCMV-b-Gal, and the luciferase reporter genes harboring 967 bp of the Mcad pro-
moter. Luciferase activity was normalized to b-Gal activity. Each value represents
mean of six independent experiments 6SD.
C)HepG2 cells were transfected with Foxa1, Foxa2, or Hybrid expression vectors,
pCMV-b-Gal, and the luciferase reporter genes harboring 831 bp of the CptI pro-
moter. Luciferase activity was normalized to b-Gal activity. Each value represents
mean of six independent experiments 6SD. *p% 0.05; ***p% 0.001.CELL METABOLISM : FEBRUARY 2006
Foxa2/Pgc-1b regulate TAG metabolism/VLDL secretionFigure 2. Foxa2 but not Foxa1 is an interaction part-
ner of Pgc-1b
A) HepG2 cells were transfected with Foxa1, Foxa2,
or Hybrid-Gal4 DNA binding domain expression vec-
tors, an expression vector for a fusion protein of
VP16AD and Pgc-1a, pCMV-b-Gal, and a Gal4-lucif-
erase reporter gene. Luciferase activity was normal-
ized to b-Gal activity. Each value represents mean of
6 independent experiments 6SD.
B) HepG2 cells were transfected with Foxa1, Foxa2,
or Hybrid-Gal4 DNA binding domain expression vec-
tors, an expression vector for a fusion protein of
VP16AD and Pgc-1b, pCMV-b-Gal, and a Gal4-lucif-
erase reporter gene. Luciferase activity was normal-
ized to b-Gal activity. Each value represents mean of
six independent experiments 6SD.
C) HEK293 cells were transfected with HA-Foxa1,
HA-Foxa2, orHA-Hybrid expression vectors together
with an expression vector for FLAG-Pgc-1b. Proteins
from whole-cell lysates were precipitated with a-HA
antibodies. Precipitates were immunoblotted and
stained using a-HA or a-FLAG antibodies.
D) HepG2 cells were transfected with expression
vectors for either FLAG-Pgc-1a or FLAG-Pgc-1b.
Proteins from whole-cell lysates were precipitated
with a-FLAG antibody. Precipitates were immuno-
blotted using a-FLAG or a-Foxa2 antibodies.
E) Foxa1, Foxa2, and FLAG-Pgc-1b were immuno-
precipitated from nuclear extracts of livers from
fasted and fed wt animals, which had been infected
with Ad-Pgc-1b. Precipitates were immunoblotted
using a-FLAG or a-Foxa2 and a-Foxa1 antibodies
to detect interaction between Foxa1, Foxa2, and
Pgc-1b.
F) Foxa1, Foxa2, and Flag-Pgc-1bwere immunopre-
cipitated from whole-cell extracts and nuclear ex-
tracts of ob/ob mice, which had been infected with
Ad-Pgc-1b. Precipitates were immunoblotted using
a-FLAGor a-Foxa2 and a-Foxa1 antibodies to detect
interactions between Foxa1, Foxa2, and Pgc-1b.
G) HEK293 cells were transfected with expression
vectors for Foxa1, Foxa2, orHybrids, aloneor in com-
bination with an expression vector of Pgc-1b, and
pCMV-b-Gal and a Mcad-luciferase reporter gene.
Each value represents the mean of six independent
experiments 6SD.
H) HepG2 cells were infected with siRNAs targeting
Pgc-1b in the presence and absence of insulin, to-
gether with pCMV-b-Gal and a MCAD-luciferase re-
porter plasmid. Luciferase activity was normalized
to b-Gal activity. Each value represents mean of six
independent experiments 6SD. *p % 0.05; **p %
0.01; ***p% 0.001.domain. If the bait and target proteins interact, the activation do-
main is brought in close contact with the DNA binding domain,
resulting in transcriptional activation of the luciferase reporter
gene. While Pgc-1a did not interact with Foxa1, Foxa2, or do-
main A (Hnf4a served as positive control; Figure 2A), we found
a significant increase in luciferase activity when assaying the in-
teraction of Pgc-1b and Foxa2 (Figure 2B). This interaction was
also observed with domain A alone, while Foxa1 did not show
any interaction with Pgc-1b (Figure 2B). The interaction between
Foxa2/domain A with Pgc-1bwas similar to that observed for in-
teraction between Pgc-1b and Hnf4a (Figure 2B). To confirm in-
teraction of Foxa2 and Pgc-1b, we coimmunoprecipitated pro-
teins from lysates of HEK293 cells that had been transfected
with either pcDNA3, HA-Foxa1, HA-Foxa2, or HA-Hybrid-Foxa
together with FLAG-Pgc-1b using an a-HA-antibody. Coprecipi-CELL METABOLISM : FEBRUARY 2006tated FLAG-Pgc-1b was detected with a-Flag-antibody (Fig-
ure 2C). Similar to the mammalian two-hybrid experiments, we
found that Foxa2 and the Foxa-hybrid, but not Foxa1, interacted
with Pgc-1b. Further conformation was obtained by overex-
pressing FLAG-Pgc-1a or FLAG-Pgc-1b in HepG2 cells. Both
proteins were precipitated using a-FLAG antibodies, and inter-
action of endogenous Foxa2 was analyzed by immunostaining
the coprecipitates with a-Foxa2 antibody. We observed an in-
teraction of Foxa2 and Pgc-1b but not with Pgc-1a (Figure 2D).
To measure interaction of Foxa2 and Pgc-1b in vivo, we precip-
itated endogenous Foxa1 and Foxa2 from (1) whole-cell extracts
of ob/obmice livers, (2) nuclear extracts of ob/obmice livers, (3)
nuclear extracts of fasted wt mice, and (4) nuclear extracts of wt
fed mice, which were infected with Ad-Pgc-1b. We observed an
interaction of Foxa2 with Pgc-1b in ob/ob whole-cell extracts101
A R T I C L Eand in fasted wt mice nuclear extracts (Figures 2E and 2F). No
interaction between Foxa1 and Pgc-1b was observed in any
animal models studied (Figures 2E and 2F).
Since we could show that Pgc-1b could interact with Foxa2
and Hybrid-Foxa, we analyzed whether Pgc-1b could augment
the transcriptional activation of a Foxa2 reporter gene.We trans-
fected HEK293 cells (which do not express Foxa genes or Pgc-
1b) with Foxa1, Foxa2, and the different hybrids, together or
without Pgc-1b, and measured luciferase activity of different re-
porter genes (Mcad and CptI promoters). We observed a signif-
icant 120% increase in transcriptional activity when transfecting
expression vectors for either Foxa2 or domain A containing Hy-
brid-Foxa2 (Hyb.) together with Pgc-1b and either Mcad or CptI
reporter gene vector (Figure 2G and data not shown). No in-
crease was observed when Foxa1 was coexpressed with Pgc-
1b, and neither did Pgc-1b augment reporter gene activity
when a Foxa1/2 hybrid expression vector was used that lacked
domain A (Figure 2G). In contrast Pgc-1a was not able to in-
crease the transactivation potential of either Foxa2 or a domain
A containing Foxa2 hybrid (data not shown). To demonstrate
that Foxa2/Pgc-1b transactivation is regulated by insulin signal-
ing, we transfected HepG2 cells with different siRNAs targeted
against Pgc-1b together with the Mcad reporter gene and ana-
lyzed the differences in transactivation in the presence or ab-
sence of insulin (Figure 2H). Transfection of siRNA#2, which re-
duces Pgc-1b expressionz60%, decreased transactivation of
the Mcad promoter by approximately 40%, similar to the effect
observed by insulin. In contrast, an ineffective siRNA (siRNA#1)
had no effect on luciferase activity. No further decrease of trans-
activation could be observed in siRNA-treated cells that were in-
cubated in the presence of insulin.
Regulation of b oxidation by Foxa2/Pgc-1b in vivo
To address whether coactivation of Foxa2 by Pgc-1b has phys-
iological relevance, we studied the metabolic effect of Foxa2
and Pgc-1b on hepatic lipid metabolism in ob/ob mice and fed
wt littermates. We used these mice as a Foxa2 loss-of-function
model since we have shown previously that Foxa2 is perma-
nently inactivated in the liver of these animals by nuclear exclu-
sion (Wolfrum et al., 2004). Mice were injected with an adenovi-
rus expressing Foxa2T156A (Ad-Foxa2T156A), which is resistant to
Akt-mediated phosphorylation and therefore not inactivated
through high levels of insulin (Wolfrum et al., 2004) and/or an ad-
enovirus expressing Pgc-1b (Ad-Pgc-1b). We have shown pre-
viously that infection of mice with constitutive active Foxa2T156A
at a titer of 109 pfu/mouse results in levels of nuclear Foxa2 that
are similar to overnight-fasted mice (Wolfrum et al., 2004; see
Figure S1 in the Supplemental Data available with this article on-
line). A recombinant adenovirus expressing only EGFP (Ad-GFP)
was used as a control. Blood was taken from the animals at day
0, 4, 9, and 14, and the animals were sacrificed on day 14. Infec-
tion of mice with Foxa2T156A led to a time-dependent decrease
in plasma glucose (Figure 3A and data not shown), an effect that
was not observed in mice infected with Ad-Pgc-1b alone. Co-
expression of Pgc-1b and Ad-Foxa2T156A also did not lead to
a further decrease of plasma glucose in these animals. Similar
results were obtained for plasma insulin levels, which did not
change in response to Ad-Pgc-1b expression alone and were
only marginally reduced in Ad-Foxa2T156A/Ad-Pgc-1b coin-
jected mice compared to Ad-Foxa2T156A-treated animals (Fig-
ure 3B and data not shown). In contrast, we measured a modest102increase in plasma TAG in mice that were infected with Pgc-1b
alone (Figure 3C and data not shown). Overexpression of Fox-
a2T156A in livers of ob/ob mice led to a significantly higher in-
crease in plasma TAG. Interestingly, even though there was
only a modest effect of Pgc-1b on plasma TAG, coexpression
of Foxa2T156A and Pgc-1b led to significant increase in plasma
TAG concentration in comparison to plasma TAG levels in ani-
mals infected with Ad-Foxa2T156A alone (Figure 3C and data
not shown). The effect of adenoviral infection was mirrored by
plasma free fatty acids (FFA), which were increased in response
to overexpression of Foxa2T156A alone as well as in combination
with Pgc-1b (Figure 3D and data not shown). Liver weight and
hepatic triglyceride content were decreased in mice that were
injected with either Ad-Foxa2T156A or Ad-Pgc-1b. Hepatic coex-
pression of both factors led to a more pronounced decrease
than that observed for the independent factors (Figures 3E
and 3F and data not shown). No effect of adenoviral Foxa2 or
Pgc-1b expression was observed on muscle triglyceride levels
(data not shown). Mitochondrial b oxidation was increased
slightly (z25%) in Ad-Pgc-1b-infected mice and doubled in re-
sponse to Ad- Foxa2T156A infection. Coexpression of both Fox-
a2T156A and Pgc-1b led to a further increase in mitochondrial
b oxidation (Figure 3G and data not shown).
We next determined the mechanism underlying the increase
in b oxidation in livers of these mice. Gene expression of several
known Foxa2 and Pgc-1b target genes was analyzed by RT-
PCR. Key enzymes of mitochondrial b oxidation, namely CptI,
Mcad, and Vlcad were upregulated in animals that were infected
with either Ad-Foxa2T156A or Ad-Pgc-1b, alone or in combina-
tion (Figures 3H and 3I). While Pgc-1b overexpression alone up-
regulated the expression of Mcad and Vlcad approximately
2-fold, Foxa2T156A increased the expression 3- to 4-fold. The
highest expression levels were observed in animals that were in-
fected with both constitutive active Foxa2 and Pgc-1b (5- to
6-fold), demonstrating that Foxa2 and Pgc-1b have a coopera-
tive effect on the expression of target genes in lipid metabolism.
Foxa2/Pgc-1b regulate VLDL secretion
To elucidate the mechanism underlying the increase in liver tri-
glyceride secretion, we first determined whether triglyceride
synthesis was increased in these mice. The effect of Foxa2
and Pgc-1b expression led to a small but significant increase
in triglyceride synthesis (Figure 4A and data not shown). Since
this increase was too small to explain the increased triglyceride
secretion, we next analyzed the localization of the secreted tri-
glycerides in circulating plasma lipoproteins. VLDL particles
constitute themajor transport systemof plasma TAGs; however,
small amounts of TAGs are also found in LDL and HDL particles.
To assess whether the increase in plasma concentration is due
to increased VLDL levels, we separated plasma lipoproteins of
the infected ob/ob mice by FPLC and analyzed the fractions
for triglyceride content. Infection of the animals with Pgc-1b
alone did not significantly change plasma VLDL levels com-
pared to Ad-GFP-infected mice (Figure 4B), while infection of
ob/ob animals with Ad-Foxa2T156A alone or in combination
with Ad-Pgc-1b led to an increase in plasma triglyceride and
VLDL concentrations (Figure 4B).
Several pathways control VLDL synthesis and secretion in
the liver. To assess which enzymes might be involved in the up-
regulation of VLDL secretion in Ad-Foxa2T156A/Pgc-1b-infected
mice, we quantified mRNA expression of genes that are knownCELL METABOLISM : FEBRUARY 2006
Foxa2/Pgc-1b regulate TAG metabolism/VLDL secretionFigure 3. Adenoviral expression of Foxa2T156 and Pgc-1b in ob/ob mice alters lipid and glucose metabolism
Twelve-week-old ob/obmice were injected with Ad-GFP, Ad-Foxa2T156A, and/or Ad-Pgc-1b via the tail vein. Mice were sacrificed at day 14. All measurements were per-
formed after a moderate 6 hr fasting period. We quantified (A) plasma glucose concentrations, (B) plasma insulin levels, (C) plasma triglyceride levels, (D) plasma FFA con-
centrations, (E) liver weight, (F) liver triglyceride content in mg/mg of liver protein, and (G) Mitochondrial b oxidation.
H) Foxa2 target-gene expression of genes involved in b oxidation was measured by RT-PCR; Gapdh served as control. n = 4 in each group.
I) Expression of genes involved in b oxidation in wt mice that were infected with Ad-GFP, Ad-Foxa2T156, and/or Ad-Pgc-1b via the tail vein was measured by RT-PCR.
Gapdh served as control. n = 4 in each group. *p% 0.05; **p% 0.01; ***p% 0.001.CELL METABOLISM : FEBRUARY 2006 103
A R T I C L EFigure 4. Foxa2 and Pgc-1b concertedly induce hepatic VLDL secretion in ob/ob mice
Twelve-week-old ob/obmice were injected with Ad-GFP, Ad-Foxa2T156A, and Ad-Pgc-1b via the tail vein. All measurements were performed after a moderate 6 hr fasting
period.
A) Triglyceride synthesis was quantified by measuring 14C-palmitic acid incorporation into triglycerides in whole-cell liver extracts.
B) Plasma of virus-treated animals was analyzed 14 days after tail-vein injection. Plasma samples (100 ml) were applied to a FPLC gel filtration column. The fractions of the
eluate were assayed for total triglycerides.
C) Foxa2 target-gene expression of genes involved in hepatic VLDL secretion was measured by RT-PCR; Gapdh served as control.
D) Expression levels of HA-Foxa2 and FLAG-Pgc-1b in whole-cell extracts from liver of infected ob/ob mice were quantified by immunoblot analysis using a-HA and
a-FLAG antibodies, TATA binding protein (Tbp) served as a loading control. n = 4 in each group. *p% 0.05; **p% 0.01; ***p% 0.001.to affect VLDL secretion, including ADP ribosylation factor 1
(Arf1), phospholipase D2 (Pld2), diacylylglycerolacyl transferase
2 (Dgat2), and microsomal transfer protein (Mtp; Wiggins and
Gibbons, 1996; Jamil et al., 1998; Stone et al., 2004; Asp et al.,
2005). We found that the mRNA levels of both Mtp and Dgat2
were increased in response to Ad-Foxa2T156A infection alone
or in combination with Ad-Pgc-1b, while Ad-Pgc-1b alone did
not have any effect (Figure 4C).Mtp protein expression in adeno-
virus-treated ob/ob mice was upregulated only marginally in
response to Pgc-1b overexpression, while Ad-Foxa2T156A infec-
tion led to a 2.6-fold increase (Figure 4D).Mice thatwere infected
with both Ad-Pgc-1b and Ad-Foxa2T156A exhibited a 6.2-fold in-
crease in Mtp, demonstrating that Pgc-1b and Foxa2 work in
concert to regulate the expression of Mtp. Comparison of Mtp
and Dgat2 expression between fasted and fed wt or ob/obmice
showed that both genes were decreased in the fed state and in
ob/ob animals compared to fasted wt littermates (Figure S2).104Analysis of the upstream regulatory sequences of the MTP
gene led to the identification of a conserved Foxa site at posi-
tion 2473 (relative to the transcription start site). To show that
MTP is a direct target of Foxa2, we performed chromatin immu-
noprecipitation experiments (ChIP) and transactivation assays
(Figure 5A). For the ChIP assay, primary hepatocytes were used,
which had been infected with an adenovirus expressing Pgc-1b
(Ad-Pgc-1b) in the presence or absence of insulin. Figure 5A
shows that in the absence of insulin Foxa2 binds to the con-
served Foxa site in the Mtp promoter, while neither Foxa1 nor
Foxo1 could be shown to bind to this promoter. Pgc-1b bound
to the same conserved site that Foxa2 occupies (Figure 5A). In-
terestingly, in the presence of insulin neither Foxa2 nor Pgc-1b
were found to bind to the Foxa2 consensus site in the Mtp pro-
moter. As a control, we analyzed binding of the same transcrip-
tion factors and cofactors to conserved Foxa2 binding sites in
the CptI and theMcad gene. Both ChIP assays produced similarCELL METABOLISM : FEBRUARY 2006
Foxa2/Pgc-1b regulate TAG metabolism/VLDL secretionresults as those observedwith theMtp promoter. We did not ob-
serve any binding of endogenous Foxa2 or Foxa1 to the Pepck
promoter, while Foxo1 strongly bound this promoter region
(Figure 5A). To quantify binding affinities, we studied binding
of Foxa1 and Foxa2 to the respective binding sites in the CptI,
Mcad, and Mtp genes by electrophoretic mobility shift assay
(EMSA) analysis. We found that in vitro Foxa2 bound to these
sites with high affinity, whereas Foxa1 DNA binding activity
could only be observed for the Mcad promoter (with z5-fold
less affinity than Foxa2; data not shown). Together, these results
demonstrate that the Foxa2 binding site in the Mtp promoter is
specific and functional in vivo.
We also quantified the transactivation potential of Foxa2 by
cloning a 1 kb promoter sequence of Mtp into a luciferase re-
porter gene vector and by determining the ability of Foxa2
and/or Pgc-1b to activate this promoter. Transactivation assays
in HEK293 cells demonstrated that Foxa2 increased luciferase
activity approximately 4-fold, while Foxa1 had no significant
effect on Mtp promoter activity (Figure 5B). Coexpression of
Figure 5. A functional and conserved Foxa2 binding site activates the Mtp pro-
moter
A) Primary hepatocytes were infected with Ad-Pgc-1b and treated for 2 hr with in-
sulin. The association of Foxa1, Foxa2, Foxo1, and Pgc-1b to the Mtp promoter
was measured by ChIP assay. Chromatin/protein complexes of each group
were precipitated with the pertinent antibody, following PCR amplification with
primer pairs specific for the corresponding regions in the Mtp promoter. Chip as-
says of the CptI, Mcad, and Pepck promoter served as control.
B)HEK293 cells were transfectedwith expression vectors for Foxa1, Foxa2, or Hy-
brids, alone or in combination with an expression vector of Pgc-1b, and pCMV-b-
Gal and a Mtp promoter-luciferase reporter gene. Luciferase activity was normal-
ized to b-Gal activity. Each value represents mean of six independent experiments
6SD. *p% 0.05; **p% 0.01; ***p% 0.001.CELL METABOLISM : FEBRUARY 2006Pgc-1b and Foxa2 led to an additional 120% increase in trans-
activation (Figure 5B). To quantify the relative contribution of the
conserved Foxa2 binding site in the Mtp promoter in compari-
son to the DR-1 element, which has been shown to mediate
PPARa- and HNF4a-dependent activation of the Mtp gene,
we generated a reporter gene construct with a mutated DR-1
motif (Ameen et al., 2005). Mutation of the DR-1 element (DR-
1mut) completely abolished transactivation by PPARa and/or
HNF4a (Figure 6A). The observed increase in transactivation of
the Mtp promoter was similar for Foxa2 and PPARa, while
HNF4a had a much lower transactivation activity (Figure 6A).
To further study the effect of these transcription factors, we
transfected the wild-type and mutated Mtp reporter constructs
into HEK293 cells and analyzed the transactivations by PPARa,
HNF4a, or Foxa2. Again, the transactivation of theMtp promoter
was similar for Foxa2 and PPARa (Figure 6B) with a significantly
lower activity of HNF4a, suggesting that both sites regulate ex-
pression of the Mtp promoter with equal potency. To directly
quantify the effect of Foxa2 on triglyceride secretion from hepa-
tocytes, we infected mouse primary hepatocytes with either
Ad-Foxa2 or Ad-Pgc-1b alone or in combination and measured
triglyceride secretion into the medium in a pulse/chase experi-
ment (Figure 7A). Cells were ‘‘pulsed’’ for 2 hr with 14C-palmitic
acid, and triglyceride secretion was ‘‘chased’’ for 4 hr after label-
ing of the cells.We observed a 4-fold induction in triglyceride se-
cretion in cells that were transfected with Ad-Foxa2 and a 5.5-
fold induction when cells were infected with Ad-Foxa2 and
Pgc-1b in combination. To assess how much of this triglyceride
secretion is linked to an increased VLDL production as evi-
denced by apoB100 secretion, we quantified the effect of
Foxa2 on apoB secretion from mouse primary hepatocytes
that were infected with either Ad-Foxa2 or Ad-Pgc-1b alone or
in combination. Cells were ‘‘pulsed’’ for 2 hr with a 35S-labeled
methionine/cystein mixture, and apoB secretion was ‘‘chased’’
for 4 hr after labeling of the cells. Secreted apoB was immuno-
precipitated and quantified by SDSPAGE/autoradiography. Fig-
ure 7B shows that Foxa2 overexpression led to a 3.5-fold
increase in apoB secretion, while coexpression of Pgc-1b in-
creased the secretion 5.5-fold. To analyze whether the effect
on apoB secretion was insulin-dependent, we infected primary
hepatocyteswith either Ad-Foxa2 or Ad-Foxa2T156A in combina-
tion with Ad-Pgc-1b and treated the cells with insulin 2 hr prior to
the experiment. Treatment of Ad-Foxa2-infected cells with insu-
lin during the study led to a decrease in Foxa2-stimulated apoB
secretion. In contrast, insulin had no effect on apoB secretion
from cells that were infected with Ad-Foxa2T156A (Figure 7C).
We also investigated whether silencing of Pgc-1b by RNAi leads
to a decrease in VLDL secretion. Pulse/chase experiments (as
described above) and apoB secretion studies were carried out
in HepG2 cells following transfection with siRNAs against the
endogenous Pgc-1b. Figure 7C shows that a z50% reduction
of Pgc-1b mRNA by siRNA#2 led to a 2- to 3-fold decrease in
apoB secretion compared to mock-transfected cells using an
ineffective siRNA (siRNA#1). These results demonstrate that
Foxa2 and Pgc-1b mediate the insulin-regulated inhibition of
VLDL secretion in hepatocytes.
Discussion
In this study, we have identified a region in Foxa2, located be-
tween the winged helix and the C-terminal transactivation105
A R T I C L Edomain, which is responsible for recruiting the transcriptional
coactivator Pgc-1b to Foxa2. Together, these two factors regu-
late the expression of genes involved in lipid b oxidation and tri-
glyceride synthesis/secretion, thereby controlling hepatic lipid
content. Inhibition of the Foxa2/Pgc-1b complex by insulin leads
to a decrease in apoB-dependent VLDL secretion, while consti-
tutive active Foxa2T156A is resistant to this effect.
Figure 6. PPARa and Foxa2 are transcriptional activators of the Mtp promoter
A) HepG2 cells were transfected with expression vectors for Foxa1, Foxa2,
PPARa, or PPARg, alone or in combination with an expression vector for Pgc-
1b, and pCMV-b-Gal, and aMtp-luciferase reporter genewith orwithout amutation
in the DR-1 element (Ameen et al., 2005). PPARa and PPARg activity was stimu-
lated by addition of Wy14,643 and rosiglitazone, respectively. Luciferase activity
was normalized to b-Gal activity.
B) HEK293 cells were transfected with expression vectors for Foxa1, Foxa2, or
PPARa, alone or in combination with an expression vector for Pgc-1b, and
pCMV-b-Gal and a Mtp-luciferase reporter gene with or without a mutation in
the DR-1 element (Ameen et al., 2005). Luciferase activity was normalized to b-
Gal activity. Each value represents mean of six independent experiments 6SD.
*p% 0.05; **p% 0.01; ***p% 0.001.106Even though Foxa1 and Foxa2 are highly homologous and
can exhibit similar transactivation and DNA binding capabilities
in vitro and display an overlapping tissue expression pattern
(Besnard et al., 2004), it is still unclear whether these factors reg-
ulate gene expression via similar mechanisms or by indepen-
dent pathways. It was recently suggested that Foxa1 and
Foxa2 compensate for each other in regulating lung and liver
gene expression using a tissue-specific double-knockout ap-
proach (Lee et al., 2005; Wan et al., 2005). It has to be noted,
however, that these genetic studies cannot distinguish between
a compensatory function and a synergistic function of both fac-
tors involving a set of target genes. In contrast, promoter analy-
ses of liver-enriched genes (e.g., transthyretin) have been shown
to selectively bind Foxa2 but not Foxa1 (Kaestner et al., 1999). In
addition, several documented genetic models provide evidence
that either factor cannot compensate for the loss of the other.
For example, despite coexpression of Foxa1 and Foxa2 in pan-
creatic a cells and similar activation of the glucagon promoter
in vitro, Foxa1 mice die shortly after birth due to impaired gluca-
gon secretion (Kaestner et al., 1999; Shih et al., 1999), suggest-
ing that Foxa2 cannot compensate for the loss of Foxa1 expres-
sion. Similarly, pancreatic b cell-specific ablation of Foxa2
results in unregulated insulin secretion, whereas insulin secre-
tion can still be regulated in mice with Foxa1 deficiency (Shih
et al., 1999; Lantz et al., 2004). Therefore, one explanation of
how Foxa1 and Foxa2 maymediate differential gene expression
is by specific posttranslational modifications and/or cofactor in-
teractions that are not accounted for by in vitro assays and could
therefore contribute to the observed in vivo differences between
Foxa1 and Foxa2.
We have shown recently that Foxa2 is inactivated by insulin
mediated phosphorylation and nuclear exclusion, while Foxa1
is not subject to regulation by insulin (Wolfrum et al., 2003). In
this study, we have demonstrated that Foxa2, but not Foxa1, in-
teracts with Pgc-1b to coactivate gene expression. Even though
Foxa2 and Foxa1 show a high sequence homology (>90%) in the
DNA winged helix and transactivation domains I–IV (Figure 1A),
the 74 amino acid residue spanning domain A (Foxa2266–340),
which we identified to be responsible for the interaction between
Foxa2 and Pgc-1b, is not conserved between Foxa1 and Foxa2
(homology <9%). Several studies have addressed interaction
between members of the Pgc family and transcription factors,
and themost commonmotif reported to facilitate interaction ap-
pears to be a leucine-rich region (LXXLL). Because this motif
was shown to be responsible for interaction with different tran-
scriptions factors, it was suggested that it was mandatory for
the interaction between a Pgc familymember and a transcription
factor. Interestingly, the domain we identified, in itself sufficient
to interact with Pgc-1b, does not harbor such a sequence motif.
Recent studies, however, have shown that Pgc-1b can also in-
teract with transcription factors via other motifs, as the interac-
tion of Pgc-1bwith Srebp and Lxr is not dependent on an LXXLL
motif (Lin et al., 2005). Interestingly, a comparison of the interac-
tion domain in Srebp and the 74 aa domain responsible for
Foxa2 and Pgc-1b interaction identified by us shows sequence
similarity (Figure S3). However, a more detailed analysis of the
interaction is necessary to elucidate the exact structural basis
for the interaction between Foxa2 and Pgc-1b.
It was previously shown that overexpression of Pgc-1b leads
to an induction of genes involved in lipid b oxidation (Lin et al.,
2002; Lin et al., 2005). We observe here a concomitant increaseCELL METABOLISM : FEBRUARY 2006
Foxa2/Pgc-1b regulate TAG metabolism/VLDL secretionFigure 7. Foxa2 and Pgc-1b induce apoB secretion from primary hepatocytes
A) Primary mouse hepatocytes were infected with either Ad-Foxa2 or Ad-Pgc-1b. The cells were pulsed with 14C-palmitic acid for 30min and incorporation of the label into
secreted triglycerides was measured by extraction of the lipid fraction followed by liquid scintillation counting. Each value represents the mean of nine independent ex-
periments 6SD.
B) Primary mouse hepatocytes were infected with either Ad-Foxa2 or Ad-Pgc-1b. The cells were pulsed with 35S-methionine for 2 hr, and secretion of radiolabel was
chased for 4 hr in DMEM. ApoB was immunoprecipitated from the medium samples with a polyclonal a-apoB antibody. After immunoprecipitation the apoB protein se-
cretion was quantified by SDS-PAGE, autoradiography, and densitometry. Each value represents the mean of six independent experiments 6SD.
C) Primary mouse hepatocytes were infected with either Ad-Foxa2, Ad-Foxa2T156A, and cells were treated with insulin 4 hr prior to the start of the experiment. Pulse/chase
experiments were performed as described above. The expression levels of HA-Foxa2 were quantified using a-HA antibodies. Tbp served as a loading control.
D) HepG2 cells were transfected with two different siRNAs against Pgc-1b (si-Pgc-1b #1, #2). Pulse/chase experiments were performed as described above. Expression
levels of Foxa2, Pgc-1b, Dgat2, Mtp, and Mcad mRNA were quantified using RT-PCR. Gapdh served as loading control. *p% 0.05; **p% 0.01; ***p% 0.001.in gene expression of key enzymes in mitochondrial b oxidation
when both Foxa2 and Pgc-1b are coexpressed. However, our
experiments suggest that even though both factors lead to in-
duction of the same genes there is a degree of independency,
as Pgc-1b alone is sufficient to activate gene expression of
Mcad and CptI in livers of ob/ob and fed wt animals where
Foxa2 is constitutively inactivated. This suggests that Pgc-1b
regulates the expression of these genes not only via interaction
with Foxa2 but also by interacting with other transcription fac-
tors. Since it was reported that PPARa is an interaction partner
of Pgc-1b (Lin et al., 2002), it is to be expected that interaction of
these factors will lead to an increase in target-gene expression
of genes involved in mitochondrial b oxidation in the absence
of active Foxa2. Interestingly, high-fatty acid concentrations in-
duce Pgc-1b expression, while at the same time activating the
transcriptional activity of PPARa, thereby leading to an in-
creased metabolism of fatty acids. This could be part of a feed-
back loop that controls catabolism of fatty acids, which act both
as signaling molecules and metabolites (Lin et al., 2005).
While the small increases in expression levels of b oxidation
genes in hepatocytes infected with Ad-Pgc-1b alone suggest
that Pgc-1b has amodest ability to activate b oxidation indepen-
dently of Foxa2, probably by coactivating PPARa, the effect of
Pgc-1b on triglyceride metabolism seems to be more or less ex-
clusively mediated by Foxa2. This is evidenced by the fact thatCELL METABOLISM : FEBRUARY 2006Pgc-1b fails to significantly induce plasma triglyceride levels or
expression of either Mtp or Dgat2 in ob/ob or fed wt mice where
Foxa2 is constantly inactivated, while infection of wt rats which
could be expected to have active nuclear Foxa2 with Ad-Pgc-1b
led to a significant increase in VLDL secretion (Lin et al., 2005).
Furthermore, the induction of apoB-dependent VLDL secretion
from primary hepatocytes by Pgc-1b can be blocked by the
addition of insulin and can be reversed by transfecting the
cells with an insulin resistant Foxa2T156A, which demonstrates
that the effect of Pgc-1b on triglyceride secretion is PPARa
independent.
It has recently been shown that Pgc-1b interacts with Srebp
and Lxr, and this interaction has been correlated to an increase
in hepatic triglyceride secretion (Lin et al., 2005). Even though
there is good evidence that Pgc-1b interacts with both transcrip-
tion factors in vitro, the importance for the in vivo function of this
interaction remains elusive for several reasons. First, transgenic
overexpression of Srebp in the liver leads to lipid accumulation
and reduced plasma triglyceride levels in comparison to wt
animals (Shimano et al., 1996). In contrast, adenoviral-mediated
Pgc-1bexpression in liver lowershepatic triglyceridecontentand
increases plasma triglycerides (Lin et al., 2005). Thus, Pgc-1b
has the opposite effect on hepatic triglyceride metabolism than
one of its putative target genes. Second, induction of Lxr expres-
sion in the liver through its synthetic activator T0901317 leads to107
A R T I C L Ehepatic lipid accumulation (Grefhorst et al., 2002). Even though
these mice have increased VLDL secretion rates, no increase
in plasma VLDL steady-state levels are observed after agonist
treatment for 4 days. Therefore, the phenotype observed after
activating a putative target of Pgc-1b is the opposite of what is
observedwhenmice are infectedwith Ad-Pgc-1b. Third, Ldlr ex-
pression, which is increased in response to both Lxr and Srebp
induction in the liver, is not regulated by Pgc-1b (Lin et al.,
2005), suggesting that Pgc-1b is not the main activator for these
transcription factors in the liver. Since Pgc-1b in addition to liver
is highly expressed in muscle and fat, it is possible that tissue-
specific differences exist and that both Srebp and Lxr coactiva-
tion throughPgc-1b is important for controllinggene regulation in
other tissues beside liver.
The increase in serum triglycerides of mice injected with Ad-
Foxa2T156A/Pgc-1b is most likely the result of induction of Mtp
and Dgat2 expression. Dgat2 catalyzes the esterification reac-
tion of diacylglycerol to triglycerides and is highly expressed in
the liver (Cases et al., 2001; Lardizabal et al., 2001). Mice lacking
Dgat2 exhibit early lethality and are severely depleted of triglyc-
erides in tissues and plasma, a defect that cannot be compen-
sated by Dgat1, another member of the acyl-CoA:cholesterol
acyltransferase gene family (Stone et al., 2004). This suggests
that Dgat2 is the enzyme responsible for the majority of TAG
synthesis in mice. Since the de novo triglyceride synthesis is in-
creased only marginally in animals infected with Ad-Foxa2T156A/
Ad-Pgc-1b, it is most likely that this increase in triglyceride syn-
thesis only plays aminor role in the observed increase in plasma
triglycerides. Changes in Mtp expression or activity have also
been linked to altered plasma triglyceride levels and VLDL se-
cretion. Pharmacological inhibition of Mtp leads to a dose-
dependent decrease of secretion of apoB-containing lipopro-
teins by HepG2 cells, WHHL rabbits, rats, and humans (Jamil
et al., 1996; Benoist et al., 1996; Haghpassand et al., 1996;
Chandler et al., 2003). HeterozygousMtp-deficientmice have re-
duced rates of apoB secretion, and plasma apoB levels are 70%
of those in wt mice (Raabe et al., 1998). More importantly for our
study, augmented Mtp activity over basal levels has been re-
ported to increase apoB secretion in HepG2 cells (Jamil et al.,
1998). Furthermore, an z4-fold overexpression of Mtp by re-
combinant adenoviral infection in mice leads toz50% increase
in plasma triglycerides and a 2- to 3-fold increase in apoB secre-
tion (Liao et al., 1999). Interestingly, infection of mice with Ad-
Foxa2T156A/Ad-Pgc-1b in our study led to anz4-fold induction
of Mtp expression and a similar increase in plasma triglycerides
and apoB secretion. Together, these data suggest that the Ad-
Foxa2T156A/Pgc-1b-induced increase in apoB/VLDL secretion is
mainly due to activation of Dgat2 and Mtp expression; however,
we cannot rule out that other target genes of this complex
are also involved in this regulation. Since we could observe
a comparable increase in total triglyceride secretion and apoB
secretion, we presume that Foxa2 regulates the VLDL particle
numbers that are secreted but does not affect the size or com-
position of the VLDL particle.
Insulin has been shown to inhibit VLDL output from the liver of
rats and humans and exogenous insulin administration also sup-
presses the secretion of VLDL in humans (Durrington et al.,
1982; Patsch et al., 1983; Patsch et al., 1986). However, the mo-
lecular mechanism of this regulation has been elusive so far. In
this study, we have provided evidence that Mtp, a major regula-
tor of apoB secretion, is a direct transcriptional target of Foxa2/108Pgc-1b and that the physiological regulation of apoB/VLDL
secretion by hepatocytes is Foxa2 dependent. Since Foxa2 is
a direct target of the insulin/PI3-kinase/Akt pathway leading to
its phosphorylation and inactivation by nuclear exclusion, this
pathway could explain the mechanism by which insulin controls
VLDL secretion. Pharmacological intervention affecting either
Foxa2 or Pgc-1b could be used to develop novel strategies to
treat patients with lipodystrophy or hypertriglyceridemia.
Experimental procedures
Animal and metabolic studies
All animal models were maintained in C57Bl/6J background and maintained
on a 12 hr light/dark cycle in a pathogen-free animal facility. Twelve-week-old
ob/ob animals were injected via the tail vein with Ad-GFP, Ad-Foxa2T156A,
and Ad-Pgc-1b (gift from B. Spiegelman), alone or in combination at a final
dose of 109 pfu/mice. Blood was taken by retroorbital bleeding at days 1,
4, and 9, and mice were sacrificed at day 14.
Adenovirus generation
Adenoviruses were generated using the Rapid Adenovirus Production Sys-
tem (Viraquest). Viruses were designed to express GFP from an independent
promoter, in addition to Foxa2 or Foxa2T156A (Ad-Foxa2 and Ad-Foxa2T156A,
respectively). For in vivo experiments, mice were injected with 13 109 pfu of
adenovirus. Empty virus expressing only GFP served as control (Ad-GFP).
Transfection and transactivation assays
Transfection of HepG2 cells and luciferase transactivation assays were car-
ried out as described previously (Wolfrum et al., 2003).
Chromatin immunoprecipitation (ChIP)
ChIP analysis was carried out using insulin-treated HepG2 cells, which were
infected with either Ad-Foxa2, Ad-Foxa2T156A and/or Ad-Pgc-1b and the
ChIP Assay kit (Cell Signaling) according to the manufacturers protocol. All
proteins/chromatin complexes were precipitated using a-FLAG antibody.
RNA interference
HepG2 cells were grown to 60%–70% confluence and transfected with two
siRNAs against Pgc-1b (#1, NNTTGTACAGAACTACATAAG; #2, NNGACGT
GCTCTGTGATGTCA), respectively (200 pmol/6-well plate) using Fugene6
(Roche). Silencing efficiency of Pgc-1b was determined by RT-PCR.
Immunoblotting
Cytosolic and nuclear protein extracts were separated by SDS-PAGE and
transferred onto a nitrocellulose membrane (Schleicher & Schuell) by electro-
blotting. Foxa2 was detected with anti-Foxa2 antiserum (1:1000; Weinstein
et al., 1994), FLAG and HA peptides were detected with a-FLAG and a-HA
antibodies (Sigma), respectively. Membranes were incubated with primary
antibodies overnight at 4ºC.
Laboratory measurements
Blood samples were taken from mice using nonheparinized capillary tubes.
Insulin was quantified using a radioimmunoassay (Linco). Free fatty acids
were measured using a colorimetric assay system (Wako Chemicals). Glu-
cose was measured using a standard glucose sensor (Glucometer Elite,
Bayer). Triglycerides were determined using a colorimetric assay system
(Roche).
Mitochondrial b oxidation
Mitochondria from perfused livers of mice were isolated by differential centri-
fugation as described by Hoppel et al. (1979). An aliquot of freshly isolated
mitochondria was used to determine mitochondrial protein. The b oxidation
of [1-14C]palmitic acid by liver mitochondria was assessed as described by
Lang et al. (2001). CO2 trapped on the filter papers was counted for 1-
14C
activity using a scintillation counter.
Triglyceride synthesis
Two hundred milligrams of liver tissue were homogenized in oxygenized
Krebs-Ringer buffer (pH 7.4). The solution was incubated with 5 mM ofCELL METABOLISM : FEBRUARY 2006
Foxa2/Pgc-1b regulate TAG metabolism/VLDL secretionalbumin bound palmitate-1-14C and incubated for 1 hr at 37ºC. After incuba-
tion, 10% trichloroacetic acid was added and the suspension was centri-
fuged for 10 min at 14,000 3 g. The residue extracted with 2 ml of cold 5%
trichloroacetic acid. The solid residue was extracted once with 2 ml of
warm 80% ethanol, twice with 2 ml of 100% ethanol, and once with 2 ml of
ether. The alcohol and ether extracts were combined, the solvents were re-
moved by evaporation, and the residue was extracted three times with 2 ml
portions of light petroleum. The residues were resuspended in 2 ml of ace-
tone, and phospholipids were isolated by precipitation as their magnesium
complexes. The lipids remaining in the acetone solution were saponified in
4 N aqueous potassium hydroxide for 3 hr at 80ºC. After extraction of the un-
saponified fraction by light petroleum, the aqueous layer was acidified with 5
N HCL, and fatty acids were extracted with light CHCl3/ethanol (3:1) and
counted by liquid scintillation counting.
RT-PCR
Total RNA was extracted from livers and contaminating genomic DNA was
removed by treating with 5 u of RNase-free DNase-I (Roche Molecular Bio-
chemicals)/10 mg of RNA. cDNAwas synthesized usingmoloney leukemia vi-
rus reverse transcriptase with dNTPs and random hexamer primers (Invi-
trogen). The cDNAs provided templates for polymerase chain reactions
(PCRs) using specific primers at annealing temperatures ranging between
60ºC and 65ºC in the presence of dNTPs, [a-32P]dCTP, and Taq DNA poly-
merase. The primer sequences used for PCR are available upon request.
apoB pulse/chase experiments
Two days prior to the start of the experiment, HepG2 cells were plated on 110
mm culture dishes. The medium was replaced by DMEM containing 10%
FCS, 0.75 mM oleate, and 25 mM glycerol. After 20 hr, the medium was re-
moved and the cells were washed three times with HBSS buffer. The cells
were pulsed with methionine- and cysteine-free DMEM containing 150 mCi/
dish of Express-35S-labeling mix (NEN) for 2 hr. After the 2 hr pulse, radioac-
tivity was chased for 4 hr in DMEM. The chase medium was collected, and
the cells were washed several times with HBSS. apoB was immunoprecipi-
tated from the medium samples with a polyclonal sheep-anti-human apoB
antibody (Biodesign). After immunoprecipitation, the apoB proteins were
separated by SDS-PAGE, and the gel was impregnated with Amplify for
15–30 min and dried. Autoradiography of the gel was performed at 280ºC
for 6–8 days.
FPLC/triglycerides
Lipoproteins from plasma (10–100 ml) were separated by FPLC using two
Superose-6 FPLC columns in series (HR10/30) in 0.15 M NaCl, 0.01 M
Na2HPO4, 0.1 mM EDTA (pH 7.5) at 0.5 ml/min. Columns were calibrated us-
ing high and lowmolecular weight standards (Pharmacia). Triglycerides were
quantified using the TG-detection kit (Roche).
Statistical analysis
Results are given as mean 6SD. Statistical analyses were performed by us-
ing a Student’s t test, and the null hypothesis was rejected at the 0.05 level.
Linear regression was calculated using Origin (Microcal).
Supplemental data
Supplemental Data include three figures and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/3/2/99/DC1/.
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